Department of Child Psychiatry, Chiba University Hospital, Inohana 1-8-1, Chiba, 260-8670, Japan.
Ann Gen Psychiatry. 2012 May 3;11(1):12. doi: 10.1186/1744-859X-11-12.
This case is of 54-year-old female with catatonic schizophrenia, characterized by treatment resistance to the pharmacotherapy with olanzapine, risperidone, flunitrazepam, and ECT. Olanzapine and risperidone and flunitrazepam did not improve her catatonic and psychotic symptoms, and induced the extrapyramidal symptoms. The effects of ECT did not continue even for a month. However, the treatment with low-dose aripiprazole dramatically improved the patient's psychotic symptoms and extrapyramidal symptoms. The mechanisms underlying the effects of low-dose aripiprazole in this case remain unclear, but unlike other antipsychotics, aripiprazole is a dopamine D2 partial agonist. In this regard, our results suggest that aripiprazole has numerous advantages, especially in cases of stuporous catatonia and a defective general status.
本病例为 54 岁女性，患有紧张型精神分裂症，对奥氮平、利培酮、氟硝西泮和电休克治疗的药物治疗具有抗药性。奥氮平和利培酮和氟硝西泮并没有改善她的紧张和精神病症状，并引起了锥体外系症状。ECT 的效果甚至一个月都没有持续。然而，低剂量阿立哌唑的治疗显著改善了患者的精神病症状和锥体外系症状。低剂量阿立哌唑在这种情况下的作用机制尚不清楚，但与其他抗精神病药物不同，阿立哌唑是一种多巴胺 D2 部分激动剂。在这方面，我们的结果表明，阿立哌唑具有许多优势，特别是在昏迷性紧张症和一般状态不佳的情况下。
